climb profit ladder
dive patient revenue/profit dynam follow dxcm analyst
day last week note attempt quantifi manag
sales/margin target oper margin line
mostli unchang model appear realist potenti conserv
examin len per patient profit thu think
target repres achiev base case scenario revenu
softwar subscript model time upsid
remain one highest convict name reiter
buy rate price target valuat base
revenu premium high-growth med-tech peer trade
account potenti likelihood near-term upsid long-term
contribut increment market opportun forecast
per patient basi see pathway meaning increas
profit think gener
loss
given target laid manag think
could increas profit/pati model
compound annual declin sensor period leverag
on-going convers pharmaci access contribut
profit medicar patient off-set view
sales/margin goal appear achiev line
model manag note revenu profit target
oper adj ebitda margin base lower end
revenu outlook intens insulin user opportun
forecast sale impli penetr dxcm best
class cgm sensor type opportun vs today
slight adjust model account better opex assumpt
convert sales/gm forecast unchang reduc
sg slightli better oper margin somewhat off-set higher
interest expens result convert debt issu decemb
chang made note
price target usd chang
buy chang
page analyst certif
perform rel
inc design commerci
platform use peopl
profit loss summari
growth margin
continu glucos monitor cgm devic use
diabet patient monitor glycem level view
compani technolog best-in-class type platform vs
manag work secur greater patient access
pharmaci channel believ price differenti
cgm self-monitor blood glucos test smbg use
finger stick draw blood test blood sugar set narrow
 see pathway mid-teen oper margin
synchron manag target
provid dec analyst day entri new channel mix
shift pharmaci dme ramp penetr
medicar market creat volum opportun help
price target base ev/revenu
billion sale growth toward high end med-tech
believ deserv premium multipl vs peer note
sale estim includ contribut pipelin
verili addit end market japan
chang net debt
average cost debt
risk invest thesi
thesi price target could risk compani unabl
drive adopt cgm technolog level
could occur diabet patient clinician believ
technolog better easier use compani unabl
drive sensor price level make afford
well manag unabl drive leverag profit
forecast could risk
continu glucos monitor cgm devic use diabet patient
monitor glycem level view compani technolog best-in-class type
platform vs competit offer manag work
secur greater patient access pharmaci channel believ price
differenti cgm self-monitor blood glucos test smbg use finger
stick draw blood test blood sugar set narrow potenti drive greater
adopt see pathway mid-teen oper margin synchron
manag target provid dec analyst day entri
new channel mix shift pharmaci dme ramp penetr
medicar market creat volum opportun help off-set asp declin
come back dxcm first analyst day eye
compani provid framework toward margin expans decemb analyst
day mostli line prior think note focu analysi
around per patient profit disaggreg assumpt model
think initi target revenu oper adj
ebitda margin achiev line model manag note
profit target base hit lower end revenu outlook via
repres potenti upsid estim forecast revenu
impli penetr dxcm best class cgm sensor type
opportun vs today math
exhibit chang estim
sale
exhibit comparison bcm forecast target
sale
bottom line see path toward increas per patient profit
versu loss perspect
translat bcm oper margin estim compar
manag outlook year
forecast contempl mid-singl digit sensor asp declin follow
low-singl digit declin compound declin
think dxcm strategi continu posit product premium price
competit abt freestyl libr though think gap narrow due
normal competit price dynam well secur increas patient access
pharmaci channel lower asp higher margin instal base perspect
model roughli mid-teen growth rate type cgm patient
bcm estimate us cgm patient
increas penetr medicar segment sustain portion
compani overal top-lin growth profit ramp model penetr
medicar market translat sale revenu
furthermor believ per patient basi repres
profit custom stream vs commerci pay assum less spend need
support medicar patient well less riski one patient medicar
issu associ switch provid due new job patient
commerci pay thu repres solid annuiti stream view take
togeth think gener profit dollar per medicar patient
compar commerci pay patient busi ramp
contribut oper margin expans
exhibit medicar revenu profit per patient
medicar popul type
us
medicar revenu new patient
medicar revenu exist patient
us sale
ww sale
bcm estim note calcul medicar gross profit use monthli suppli cost less cog
compani margin alloc evenli across patient regardless whether commerci pay
medicar assum much lower cost need support medicar patient
signific leverag commerci pay segment allow gener
posit profit per patient also appli profit analysi
leverag assumpt commerci pay segment dxcm busi
alloc margin target ratabl period see exhibit manag
target think compani gener per patient profit vs
per patient loss channel leverag key tie
compani abil convert pharmaci access still believ forecast
requir heroic leap leverag believ oper margin target repres
achiev base case scenario compani
exhibit commerci pay profit per patient also ramp due better control
 dollar alloc commerci pay
sale growth rate north expect deliv
growth high teen signific revenu
screen monet potenti high-margin softwar subscript repres
addit wedg address market current bake forecast
believ stock deserv valu ev/sal multipl premium vs peer
price target assum multipl sale compar peer
comp set revenu growth rate includ
believ could
upsid number compani begin commerci verili type
nonintens insulin initi current factor revenu
program model
thesi price target could risk compani unabl drive adopt
cgm technolog level model could occur diabet patient
clinician believ technolog better easier use compani
unabl drive sensor price level make afford widespread
adopt well manag unabl drive leverag profit forecast
could risk
profit loss account
sale
inco oper
inco oper
inco oper
inco oper
incom equiti invest
net incom provis incom tax
provis incom tax
inco oper
inco oper
inco oper
inco oper
sharecount dilut q/q quarter y/i annual
cash equival
short-term market securit avail sale
prepaid current asset
properti plant equip net
current portion long-term debt
account payabl accru liabil
accru payrol relat expens
current portion defer revenu
prefer stock par share author none issu outstand
total liabil stockhold equiti
total liabil stockhold equiti
total liabil stockhold equiti
total liabil stockhold equiti
oper
oper
oper
oper
depreci amort
non-cash issuanc common stock
impair intang asset
chang asset liabil net effect acquisit
prepaid expens asset
account payabl accru liabil
accru payrol relat expens
defer rent liabil
total chang work capit
net cash oper
net cash oper
net cash oper
net cash oper
invest
invest
invest
invest
purchas market secur
proce matur market secur
purchas pp
acquisit net cash acquir
net cash invest
net cash invest
net cash invest
net cash invest
financ
financ
financ
financ
net proce issuanc common stock
payment acquisit relat conting consider liabil
proce issuanc convert debt net issuanc cost
proce short-term borrow
repay short-term borrow
repay long-term debt
net cash financ
net cash financ
net cash financ
net cash financ
net chang cash equival
net chang cash equival
net chang cash equival
net chang cash equival
 begin period
 end period
berenberg capit market llc rate inc
